Affinity Asset Advisors »

Dianthus Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $10M 262k 39.35

More positions owned by Affinity Asset Advisors

Insmed Com Par $.01 (INSM)
Verona Pharma Sponsored Ads (VRNA)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Xenon Pharmaceuticals (XENE)
Madrigal Pharmaceuticals (MDGL)
Apogee Therapeutics (APGE)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)
Abivax Sa Sponsored Ads (ABVX)
Mineralys Therapeutics (MLYS)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Merus N V (MRUS)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Lexeo Therapeutics (LXEO)

View all positions for Affinity Asset Advisors

Top funds holding Dianthus Therapeutics

FMR
Fairmount Funds Management
Avidity Partners Management
RA Capital Management
Wellington Management Company
Octagon Capital Advisors
Point72 Asset Management
TCG Crossover Management
Vanguard Group
BlackRock
Bain Capital Life Sciences Investors
Vestal Point Capital
Citadel Advisors
VR Adviser
Alliancebernstein

View all funds holding Dianthus Therapeutics